Member Info for mulledwine

Interim Management Statement The Board of LMS Capital ("LMS" or "the Company) is pleased to present the Company's Interim Management Statement ("IMS") as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3. This statement relates to the period from 1 July 2012 to 1 November 2012. LMS Capital is an investment company focused on small to medium sized companies in consumer, energy and business services. Following a General Meeting on 30 November 2011, the Company is undertaking a realisation strategy which aims to achieve a balance between an efficient return of cash to shareholders and optimising the value of the Company's investments. The Company's unaudited net asset value per share at 30 September 2012 was 85 pence, down 3 pence from 88 pence as at 30 June 2012. The principal factor in this decrease was unrealised currency losses as the US dollar weakened against £ sterling over the period. In the three months to 30 September 2012 we received proceeds from realisations (principally distributions from our fund interests) of £21.4 million, including £17.9 million ($28.4 million) from San Francisco Equity Partners following its sale of Method Products. In the same period calls from our outstanding fund commitments were £1.1 million. Total realisations in the first nine months of the year were £31.5 million, with fund calls of £4.9 million. Uncalled commitments to funds at 30 September 2012 were £10.6 million and the Company had cash of £51.5 million. The Directors have previously stated their aim to announce a first distribution to shareholders before the end of this year. Today we have also made a separate announcement explaining that we have published and sent a circular to shareholders setting out details of a proposed tender offer in relation to a return of up to £40 million to shareholders.

http://www.investegate.co.uk/Article.aspx?id=201211020700051561Q

Graham Stewart, Chief Executive of Faroe Petroleum plc, commented: "Faroe Petroleum adheres to a strict policy of protecting shareholder interests such that substantial development investments are only made where there is good potential for an attractive return, and unfortunately the P1161 licence does not satisfy our economic criteria. The high potential West of Shetlands area continues to be a core element of Faroe Petroleum's strategy. The Company has considerable knowledge and experience in this important region, holding a large portfolio position there, including the Glenlivet and Tornado gas discoveries, which are progressing towards development. "In addition, the Company announced on 21 September this year the acquisition of an interest in the producing East Foinaven oil field, and provisional awards of exploration licences were also announced last week which included four in the west of Shetlands area, of which three are operated by Faroe Petroleum." "In the meantime we await the results of two UK exploration wells currently being drilled, namely the N.Uist well (6.25%) (West of Shetland) and the, Spaniards East well (8.4%) (UK North Sea)."

Relinquishment of West of Shetland P1161 Licence Faroe Petroleum plc, the independent oil and gas company focusing principally on exploration, appraisal and production opportunities in the Atlantic Margin, the North Sea and Norway, announces that it intends to cease operations on the P1161 licence (Freya and Fulla), west of Shetland (Faroe Petroleum 50% and operator). In July 2011 the Company drilled an exploration well (206/5a-3) on the Fulla prospect and the targeted Clair and Whiting reservoir sands were found to be oil-bearing. Extensive modelling has since been undertaken to establish the resource potential and assess a means of economically developing the Fulla discovery in conjunction with the 1980 Freya discovery, located immediately to the south in the adjoining Block 206/10a. The results of this work confirm relatively poor oil quality, smaller than expected resource size and limited access to infrastructure. No economically viable solution has been found to bring these discoveries to development at this time, and consequently the licence will be relinquished.

http://www.investegate.co.uk/Article.aspx?id=201211020700051548Q

Stanley Gibbons Group Buy 31-Oct-12 £14,805.00 John T Byfield 7,050 @ 210.00p

Stanley Gibbons Group Buy 31-Oct-12 £26,491.08 David Martin Bralsford 12,500 @ 211.93p

Publishing Technology Buy 31-Oct-12 £49,674.24 Alan Moug 50,176 @ 99.00p

Thorntons Buy 01-Nov-12 £16,643.55 Jonathan Hart 54,569 @ 30.50p

PureCircle Ltd. (DI) Buy 31-Oct-12 £28,800.00 Paul E Selway-Swift 12,000 @ 240.00p

PureCircle Ltd. (DI) Buy 31-Oct-12 £59,875.00 Tan Boon Seng 25,000 @ 239.50p

Valuation: Discount at the wider end of its range IAT’s discount has moved in a range of 5% to 10% over much of the last three years, and currently stands at 9.4%. The board intends to tender for 15% of the share capital at a 2% discount to NAV less costs, if the average discount exceeds 10% in the year to 30 April 2013, or an implied average 9.2% over the balance of the period.

http://www.edisoninvestmentresearch.co.uk/researchreports/IATOUtlook011112.pdf

http://www.investegate.co.uk/Article.aspx?id=201211011430021328Q

"If these attributes are also demonstrated in clinical studies, we believe that Theliatinib could become an important therapy in this area," said Christian Hogg, Chief Executive Officer of Chi-Med.

Hutchison MediPharma Limited initiates Phase I clinical study with its novel EGFR inhibitor Theliatinib London: Thursday, 1 November 2012: Chi-Med announced that Hutchison MediPharma Limited ("HMP"), its majority owned R&D company, initiated the first-in-human Phase I clinical trial of Theliatinib (HMPL-309). This is the fourth oncology compound from the internal discovery programmes of HMP to enter into clinical development in China. Theliatinib is a novel, orally active small molecule inhibitor targeting the wild type epidermal growth factor receptor ("EGFR") or resistant EGFR tumours. The first patient was dosed on 30 October 2012. The primary objectives of the Phase I study are to evaluate its safety and tolerability in patients with advanced solid tumours and to determine its maximum tolerated dose. This study will also evaluate its preliminary efficacy against non-small cell lung cancer ("NSCLC"), determine the pharmacokinetics of Theliatinib under single dose and repeat doses and explore the relationship between the Theliatinib's activity and certain biomarkers. In pre-clinical studies, Theliatinib demonstrated strong anti-tumour activity against EGFR wild type tumours at doses that are expected to be well tolerated. Theliatinib was also found to have good pharmacokinetic properties and a favourable safety profile. These studies also exhibited good tissue distribution and stronger anti-tumour activity in EGFR wild type and EGFR resistant tumours, compared with first generation small molecule EGFR inhibitors.

http://www.investegate.co.uk/Article.aspx?id=201211010700059475P

Jeff Harris, Chairman of Cookson, commented: "After significant progress in each of our two main businesses in recent years, and following a detailed strategic review, we are clear that a demerger remains in the best interests of those businesses and therefore our shareholders. Alent and Vesuvius will both be significant stand-alone entities - financially strong, global, and leaders in their respective technologies and end-markets. There is very limited operational or end-market overlap between the two, and both will be much better placed to maximise their potential following the Demerger. Strong Boards and management teams are now in place to take both Alent and Vesuvius forward independently, and to create significant value for shareholders over time."

ROYAL DUTCH SHELL PLC THIRD QUARTER 2012 INTERIM DIVIDEND The Board of Royal Dutch Shell plc ("RDS") today announced an interim dividend in respect of the third quarter of 2012 of US$0.43 per A ordinary share ("A Share") and B ordinary share ("B Share"), an increase of US$ 0.01 on the equivalent US dollar dividend for the same quarter last year. RDS provides eligible shareholders with a choice to receive dividends in cash or in shares via a Scrip Dividend Programme ("the Programme"). For further details please see below. Details relating to the third quarter 2012 interim dividend It is expected that cash dividends on the B Shares will be paid via the Dividend Access Mechanism from UK-sourced income of the Shell Group. Per ordinary share Q3 2012 RDS A Shares (US$) 0.43 RDS B Shares (US$) 0.43 Cash dividends on A Shares will be paid, by default, in euro, although holders of A Shares will be able to elect to receive dividends in pounds sterling. Cash dividends on B Shares will be paid, by default, in pounds sterling, although holders of B Shares will be able to elect to receive dividends in euro. The pounds sterling and euro equivalent dividend payments will be announced on December 7, 2012. Per ADS Q3 2012 RDS A ADSs (US$) 0.86 RDS B ADSs (US$) 0.86 Cash dividends on American Depository Shares ("ADSs") will be paid, by default, in US dollars.

http://www.investegate.co.uk/Article.aspx?id=20121101070035P877B